RIFAPENTINE TABLETS DIN 02565706
Health Canada record
| Active ingredient(s) | RIFAPENTINE 150 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J04AB05 RIFAPENTINE |
| Original market date | |
| Current status date | 12-Feb-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Macleods Pharmaceuticals Limited — licence , not currently licensed, last inspection rating C (2025-05-05).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36895 | 2026-02-12 | New Drug Submission (NDS) |
International API supply for RIFAPENTINE
2 active FDA Drug Master Files.
Request a quote for RIFAPENTINE TABLETS